Various preclinical studies have shown the dependence of leukemic lymphoblasts on BCL-2 and BCL-XL and, accordingly, the antileukemic activity of BCL-2/BCL-XL inhibitors in ALL models [107,108,109]. This evidence concerns the gene BCL2L1 and acute lymphoblastic leukemia.